Filing Flows › Intellia Therapeutics (NTLA) › Stock forecast & fair value
Intellia Therapeutics (NTLA) stock forecast and price target
Intellia Therapeutics (NTLA) trades at $11.35. 18 analysts' median price target is $15.50 (+37%), from $8.00 to $61.00.
Intellia Therapeutics' latest quarter
Intellia Therapeutics, Q3 2026: revenue $7.2M (-48% year over year), net loss $127M, operating cash flow −$85.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for NTLA stock?
The median of 18 analysts' 12-month targets is $15.50, +37% from $11.35; the range is $8.00 to $61.00. The average rating is buy.
Does Intellia Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is NTLA stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.